Y-box-binding protein 1 (YB-1) is an oncogenic transcription factor whose overexpression and nuclear localization is associated with tumor progression and drug resistance. Transcriptional activation of YB-1 in response to genotoxic stress is believed to occur in the cytoplasm through sequence-specific endoproteolytic cleavage by the 20S Proteasome, followed by nuclear translocation of cleaved YB-1. To study the proteolysis model, we developed a two-step affinity purification of endogenous YB-1 protein species and characterized the products using mass spectrometry. Whereas full-length YB-1 was readily identified, the smaller protein band thought to be activated YB-1 was identified as hnRNP A1. An antibody specific for YB-1 was generated, which revealed only one YB-1 species, even after genotoxic stress-induced nuclear YB-1 translocation. These findings warrant re-evaluation of the mechanism of YB-1 nuclear translocation and transcriptional activation. The relationship between nuclear YB-1 and tumor progression may also have to re-evaluated in some cases.
Introduction
Y-box-binding protein 1 (YB-1) is an oncogenic transcription factor containing a conserved Cold-Shock Domain (Figure 1a) , which binds to Y-box sequence (5 0 -CTGATTGGCCAA-3 0 ) DNA in eukaryotic promoters (Wolffe, 1994) . In addition to transcriptional regulation of genes involved in DNA repair and cell cycle progression, YB-1 regulates expression of the multidrug resistance-1 (MDR1) gene (Asakuno et al., 1994) . On exposure to DNA-damaging agents, such as UV or cisplatin, YB-1 induces expression of the MDR1 P-glycoprotein transporter pump through binding to a Y-box within the MDR1 promoter. MDR1 induction by YB-1 is manifest by the correlation between drug resistance of breast cancers and YB-1 overexpression (Bargou et al., 1997) . Furthermore, immunohistochemical analysis of a variety of drug-resistant cancers and cell lines has established a relationship between nuclear YB-1, tumor drug resistance and poor patient outcome (Oda et al., 1998 (Oda et al., , 2003 Shibahara et al., 2001; Kohno et al., 2003; Gimenez-Bonafe et al., 2004; Chatterjee et al., 2008) .
The association of nuclear YB-1 with tumor progression and drug resistance has stimulated research into the molecular mechanism of YB-1 transcriptional activation. A mechanistic picture has emerged, wherein transcriptionally inactive YB-1 is associated with mRNAs in the cytoplasm and is activated as a transcription factor through a proteolytic cleavage event, followed by translocation to the nucleus. Thrombin stimulation of endothelial cells was observed to induce cleavage of YB-1, resulting in loss of the cytoplasmic retention signal ( Figure 1a ) and concomitant activation of YB-1 as a nuclear species (Stenina et al., 2000) . Further investigation has led to the hypothesis that this proteolytic activation is generally associated with genotoxic stress, and that cleaved nuclear YB-1 is the active transcription factor and a distinct species from full-length cytoplasmic YB-1 (Sorokin et al., 2005) . A key element of this mechanism is that cleaved YB-1 is generated by the 20S Proteasome through sequence-specific endoproteolytic cleavage between amino acids 219/220 ( Figure 1a ) (Sorokin et al., 2005) .
Proteolytic activation of full-length YB-1 to a cleaved nuclear species can account for the association of nuclear YB-1 and activation of its target genes, notably MDR1. The proposed mechanism is also consistent with studies reporting the presence of two YB-1 species detectable by western blotting (Ohga et al., 1996; Berquin et al., 2005; Guay et al., 2008) that are associated with the nucleus (Berquin et al., 2005) and stress treatment (Guay et al., 2008) . However, some observations are inconsistent with the proteolysis model. For example, strong induction of cleaved YB-1 in response to cisplatin was not accompanied by a concomitant decrease of full-length YB-1 (Sorokin et al., 2005) , and in a separate study, neither paclitaxel nor cisplatin induced YB-1 cleavage under conditions in which nuclear translocation of YB-1 was occurring (Fujita et al., 2005) . Furthermore, a full-length YB-1 bearing a C-terminal GFP translocated to the nucleus; yet, according to the proteolysis model, the GFP portion of the protein should have remained in the cytoplasm (Raffetseder et al., 2003) .
The discrepancies in the literature may be partly explained by a lack of consistency or characterization of YB-1 antibodies employed for western blotting, although interpretation may be further complicated by aberrant electrophoretic mobilities of YB-1. The molecular mass of YB-1 is 35.9 kDa; however, the protein displays an electrophoretic mobility of B48 kDa, whereas the cleaved form migrates at B37 kDa (Sorokin et al., 2005) .
Immunohistochemical studies of different human malignancies have used antibodies directed against both the N-and C-terminal regions of YB-1, often revealing high levels of YB-1 in the nucleus (Oda et al., 1998 (Oda et al., , 2003 Shibahara et al., 2001; Ito et al., 2003; GimenezBonafe et al., 2004; Chatterjee et al., 2008) . However, if YB-1 requires proteolytic removal of the C-terminal cytoplasmic anchor for nuclear translocation, then immunohistochemical studies performed with C-terminal antibodies have presumably detected an alternate protein and require re-evaluation. Thus, the value of nuclear YB-1 as a prognostic marker for tumor progression is directly linked to its mechanism of activation.
In this study, we sought to understand the molecular mechanism behind YB-1 localization. Using the proteolytic cleavage mechanism as an experimental framework, our initial aim was to characterize all endogenous YB-1 species using protein purification and mass spectrometry (MS). Our unequivocal identification of proposed YB-1 species as an unrelated protein has revealed the source of previous conflicting experimental observations and calls for reassessment of the mechanism of YB-1 activation.
Results
We began by reproducing documented observations of YB-1 localization and nuclear translocation in response to stress (Ohga et al., 1996; Sorokin et al., 2005) . We used two YB-1 antibodies, one with an N-terminal epitope and the other with an epitope that is C-terminal to the proposed site of proteolytic cleavage by the 20S Proteasome ( Figure 1a , epitopes b and c). Immunofluorescence of untreated human lung carcinoma A549 cells revealed predominantly cytoplasmic YB-1 with both antibodies (Figure 1b) . On UV irradiation, an increase in nuclear YB-1 was observed with the N-terminal antibody (epitope b); treatment with Actinomycin D afforded a stronger induction of nuclear YB-1, with X80% of cells showing intense nuclear staining. In contrast, the distribution of YB-1 observed with the C-terminal antibody (epitope c) was essentially unchanged. These observations are consistent with proteolytic activation of YB-1 followed by nuclear translocation, wherein nuclear YB-1 has lost the C-terminal epitope. This mechanism is also consistent with western analysis of untreated A549 cells; the N-terminal epitope ( Figure 1c , top) provided two bands, at B48 and B37 kDa, whereas the C-terminal epitope ( Figure 1c , bottom) provided only the 48-kDa band. However, when we tried to knockdown these protein species using RNAi against YB-1, the 37-kDa band was unaffected, whereas the 48-kDa band was depleted by X90% ( Figure 1c ).
In light of these conflicting observations, we set out to characterize these bands unequivocally using protein purification and MS. To do this, we optimized induction of the proposed cleaved B37 kDa form of YB-1. Working with A549 cells, a X5-fold induction of the 37-kDa band was obtained on treatment with Actinomycin D (5 mM, 20 h) ( Figure 2a ). Induction of cleaved YB-1 was accompanied by a reduction of full-length YB-1; however, the level of reduction did not quantitatively match the level of induction.
To identify the induced B37-kDa product, we developed a two-step affinity purification of YB-1 that provided material in sufficient purity for MS. YB-1 was immunopurified with the N-terminal antibody (epitope b) to capture both YB-1 species. The immunoprecipitate was suspended in buffer containing excess peptide antigen to allow dissociation of YB-1 from immobilized antibody. The second purification step is based on the high affinity of a Cold-Shock Domain-containing protein (Bp8, bearing homology with YB-1) to the single-stranded pyrimidine-rich sequence 5 (Horwitz et al., 1994) . The corresponding 5 0 -biotinylated DNA was immobilized onto Neutravidin beads, providing the affinity reagent. Immunopurified YB-1 was incubated with the ssDNA-modified beads to capture the 48-and 37-kDa species. Protein products were separated by SDS-polyacrylamide gel electrophoresis and visualized with Coomassie ( Figure 2b) .
The change in product distribution on treatment with Actinomycin D, as observed by western analysis (Figure 2a) , was conserved when assessed by Coomassie staining of purified protein (Figure 2b ). However, peptide sequencing of products by MS provided unexpected results. Band 1 at B48 kDa was the largest product bearing YB-1 sequence (59% sequence coverage, Figure 2c ), supporting its assignment as full-length YB-1. Bands 2 and 3 were also identified as YB-1 species (sequence coverage of 42 and 46%, respectively). Band 4 afforded YB-1 sequence (33% sequence coverage), albeit at weak intensity; however, the major protein in this band was hnRNP A1. The data from bands 1-4 are inconsistent with sequence-specific endoproteolytic cleavage between amino acids 219/220. At least three YB-1 species distinct from the full-length YB-1 were observed. Furthermore, sequence coverage in the B37-kDa species (band 4, Figure 2d ) extended past amino acids 219/220, the proposed site of cleavage by the 20S Proteasome. MS data from products obtained after stress treatment with Actinomycin D were also inconsistent with the proposed cleavage mechanism. Band 5 was identified as full-length YB-1; this was the only band from treated cells to provide peptide sequence for YB-1 (proteins between bands 5 and 6 were keratins). Band 6, the product of induction, contained only hnRNP A1 ( Figure 2e) ; no YB-1 peptides were detected.
The MS data indicate that although shorter forms of YB-1 exist, they make up a small proportion of total YB-1 protein, in contradiction with conclusions drawn exclusively from western analysis (Figure 2a) . Unexpectedly, the data reveal that the B37 kDa protein that is induced is in fact hnRNP A1, and not YB-1. To confirm induction of hnRNP A1, the A549 lysates were analysed by western probing against hnRNP A1, revealing the same induction on treatment with Actinomycin D (Figure 2a, bottom) . The decrease in the amount of YB-1 protein after treatment with Actinomycin D (Figure 2b ) is likely a consequence of Actinomycin-induced arrest of YB-1 transcription and protein synthesis rather than a specific proteolytic event.
Smaller forms of YB-1 that were identified (Figure 2b , bands 2, 3, 4) may be products of non-specific proteolytic degradation. Regardless of the mechanism of formation, these smaller YB-1 species were observed before genotoxic stress and thus do not lend support to the proteolysis model of YB-1 activation.
We corroborated our biochemical characterization with a cell-based approach using RNAi knockdown. Working with A549 cells, RNAi directed against hnRNP A1 resulted in X95% knockdown of the 37-kDa species (Figure 3a, lane 2) . Conversely, RNAi directed against YB-1 resulted in X90% knockdown of the 48-kDa species (Figure 3a, lane 3) . Full-length YB-1 and hnRNP A1 were unresponsive to control RNAi bearing identical nucleotide composition but in scrambled sequence (Figure 3a, lane 4) . Similar results were obtained using the MCF7 breast cancer cell line, albeit with slightly less efficient knock down (Figure 3b) . These results provide an independent confirmation of our conclusions drawn from MS: the 37-kDa species is predominantly hnRNP A1, whereas YB-1 constitutes a minor component. The detection of YB-1 in this band by MS (Figure 2b-band 4, Figure 2d ) and the efficient knock down of the 37-kDa band when analysed by western analysis (Figure 3a , lane 2) illustrate the extreme sensitivity of MS and the predominance of hnRNP A1 in the 37-kDa band. Further support for these results came from western analysis of hnRNP A1 RNAi probed with an hnRNP A1 antibody, which confirmed the knock down (Figure 3a, lane 2, bottom) . The amount of full-length YB-1 was unaffected by treatment with UV or cisplatin (Figure 3 , lanes 5, 6), consistent with previous observations (Sorokin et al., 2005) , whereas probing against hnRNP A1 revealed induction of the 37-kDa band. In addition to studies with the epitope b antibody to YB-1, we also tested several other YB-1 antibodies with N-terminal epitopes. Similar to the above observations, we frequently found cross-reaction with hnRNP A1. Two examples of this are shown in Supplementary Figures 1 and 2 . In a further experiment, we used the antibody from Sorokin et al. (2005) . In this case the antibody reacted strongly with two protein species and weakly with YB-1 (Supplementary Figure 3) .
To confirm that only one YB-1 species exists, even after genotoxic stress, we generated a YB-1 antibody using the first 12 amino acids of YB-1 as the epitope (Figure 1a . In no cases were other YB-1 species observed, nor was the level of YB-1 affected by UV or cisplatin.
With an antibody specific for YB-1, the localization status of YB-1 can be accurately assessed. Immunofluorescence analysis of untreated A549 cells revealed predominantly cytoplasmic localization (Figure 5a ) as in Figure 1b . However, after UV or cisplatin treatment, discernable nuclear translocation was observed (confirmed by confocal Z-stacks, data not shown), although the level varied significantly from cell to cell and the staining was frequently punctuate, unlike the uniform staining observed in Figure 1b . As a further demonstration of YB-1 nuclear translocation in the absence of proteolytic processing, levels of YB-1 from cytoplasmic-and nuclear-fractionated extracts were assessed by western analysis before and after stress (Figure 5b, epitope c) . In the absence of genotoxic stress, B95% of cellular YB-1 was in the cytoplasm; on treatment with cisplatin a three-to fourfold increase in the nuclear component was observed, but the bulk of YB-1 protein still remained in the cytoplasm. Thus, genotoxic stress-induced nuclear translocation of YB-1 in the absence of proteolytic processing has been shown using two different techniques and two different antibodies.
Discussion
Immunohistochemistry has established an association between high levels of nuclear YB-1, tumor progression and drug resistance; nuclear YB-1 is therefore regarded as a poor prognostic indicator of patient outcome (Oda et al., 1998 (Oda et al., , 2003 Shibahara et al., 2001; Kohno et al., 2003; Gimenez-Bonafe et al., 2004; Chatterjee et al., 2008) . We sought to evaluate the proposed proteolytic mechanism of YB-1 nuclear activation, given its direct relevance to the validity of the numerous immunohistochemical studies performed with C-terminal YB-1 antibodies. To investigate the proteolysis model, we performed purification and MS analysis of endogenous YB-1 protein. Whereas full-length YB-1 was readily identified before and after genotoxic stress, we found that the 37-kDa species proposed to be activated YB-1 generated from proteolysis of full-length YB-1 is hnRNP A1. Our conclusion is supported by (1) identification of hnRNP A1 by MS, (2) hnRNP A1 by western analysis, (3) RNAi knockdown against hnRNP A1 and (4) generation of an antibody against YB-1 that recognizes one species on western blot, even after genotoxic stress. The MS data in particular are inconsistent with the proteolysis model, in that every YB-1 fragment that is identified provided peptide sequence coverage past the proposed site of cleavage (between residues 219/220, Figure 1a ) by the 20S Proteasome; furthermore, these YB-1 fragments were observed only before genotoxic stress, whereas the proteolysis model would predict their presence after stress.
After establishing that no YB-1 proteolysis occurs, we re-investigated genotoxic stress-induced nuclear translocation of YB-1. That this occurs in the absence of proteolytic processing was established by two methods ( Figure 5 ). Furthermore, nuclear YB-1, as observed by immunofluorescence (Figure 5a ), varied significantly from cell to cell, both in intensity and also in distribution (diffuse or punctuate). These observations suggest a greater complexity of the YB-1 activation process that remains to be explored. Such a process may involve active transport with other proteins and/or posttranslational modifications, several of which have been identified (Sutherland et al., 2005; our unpublished data) . The potential influence of protein phosphorylation is suggested by the observation that, although the YB-1 antibody to epitope c recognizes YB-1 in its denatured form (that is, western analysis/SDS-polyacrylamide gel electrophoresis), it does not detect all the same forms of YB-1 as the antibody to epitope a (for example, immunofluorescence; unpublished observations). We have identified a phosphorylation site at serine 314, just one amino acid removed from epitope c, which might account for this difference. The role of this and five other phosphorylation sites we have identified in the YB-1 activation process forms the basis of our future research.
Why YB-1 antibodies cross-react with hnRNP A1 so frequently is not clear, as we have been unable to identify any significant similar amino acid motifs between YB-1 and hnRNP A1. However, antibodies from patients with autoimmune diseases have been found to cross-react with hnRNP A1 (Lee et al., 2006) , suggesting that the cross-reaction is some kind of molecular mimicry.
In summary, our results bear on the validity of immunohistochemical studies that have established nuclear YB-1 as a prognostic indicator of tumor progression. According to the proteolysis model, immunohistochemistry performed with C-terminal antibodies would have been detecting another protein, the C-terminal cytoplasmic anchor having been lost before nuclear translocation. In contrast, our findings indicate that studies conducted with some N-terminal antibodies are subject to cross-reaction and such data might therefore require re-evaluation.
Materials and methods
See Supplementary information, for Materials and methods.
